1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Astrocytoma – Pipeline Review, H1 2013

Astrocytoma – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 422 pages

Astrocytoma – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Astrocytoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Astrocytoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Astrocytoma. Astrocytoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Astrocytoma.
- A review of the Astrocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Astrocytoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Astrocytoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Astrocytoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Astrocytoma - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 12
Global Markets Direct Report Coverage 12
Astrocytoma Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Astrocytoma 14
Astrocytoma Therapeutics under Development by Companies 16
Astrocytoma Therapeutics under Investigation by Universities/Institutes 23
Late Stage Products 27
Comparative Analysis 27
Mid Clinical Stage Products 28
Comparative Analysis 28
Early Clinical Stage Products 29
Comparative Analysis 29
Discovery and Pre-Clinical Stage Products 30
Comparative Analysis 30
Astrocytoma Therapeutics - Products under Development by Companies 31
Astrocytoma Therapeutics - Products under Investigation by Universities/Institutes 39
Companies Involved in Astrocytoma Therapeutics Development 42
Bristol-Myers Squibb Company 42
Boehringer Ingelheim GmbH 43
F. Hoffmann-La Roche Ltd. 44
Amgen Inc. 45
Sanofi-Aventis 46
AstraZeneca PLC 47
Eli Lilly and Company 48
Genentech, Inc. 49
Antigenics, Inc. 50
MedImmune LLC 51
Merck and Co., Inc. 52
Lentigen Corporation 53
Sangamo BioSciences, Inc. 54
Plexxikon Inc. 55
Celltrion, Inc. 56
Ark Therapeutics Group plc 57
Novartis AG 58
Actelion Ltd 59
Eisai Co., Ltd. 60
Nippon Shinyaku Co., Ltd. 61
Pfizer Inc. 62
Teva Pharmaceutical Industries Limited 63
Cell Therapeutics, Inc. 64
Exelixis, Inc. 65
Aduro BioTech 66
Merck KGaA 67
Celldex Therapeutics, Inc. 68
ImmunoCellular Therapeutics, Ltd. 69
Lixte Biotechnology Holdings, Inc. 70
Fina Biotech 93
Arno Therapeutics, Inc. 94
Deciphera Pharmaceuticals, LLC 95
Vascular Biogenics Ltd. 96
Stemline Therapeutics, Inc. 97
BioCancell Therapeutics, Inc. 98
Advenchen Laboratories, LLC 99
Viral Genetics, Inc. 100
NOXXON Pharma AG 101
ChemoCentryx, Inc. 102
TVAX Biomedical, LLC 103
Sirnaomics, Inc. 104
TRACON Pharmaceuticals, Inc. 105
Nexgenix Pharmaceuticals, LLC 106
Regulus Therapeutics Inc. 107
Lee's Pharmaceutical Holdings Limited 108
Lipocine Inc. 109
DiscoveryBiomed, Inc. 110
TAU Therapeutics, LLC 111
EirGen Pharma Ltd. 112
CytoVac A/S 113
Ampio Pharmaceuticals, Inc. 114
CytomX, LLC. 115
Astrocytoma - Therapeutics Assessment 116
Assessment by Monotherapy Products 116
Assessment by Combination Products 117
Assessment by Route of Administration 118
Assessment by Molecule Type 121
Drug Profiles 124
talampanel - Drug Profile 124
trebananib - Drug Profile 126
Gliadel Wafer - Drug Profile 169
bafetinib - Drug Profile 170
cilengitide - Drug Profile 172
cabozantinib - Drug Profile 174
lucanthone hydrochloride - Drug Profile 176
DCVax-L - Drug Profile 178
PX-866 - Drug Profile 180
TG-4023 - Drug Profile 182
SL-301 - Drug Profile 184
SB-313 - Drug Profile 185
LG-631 - Drug Profile 186
VB-111 - Drug Profile 188
AR-67 - Drug Profile 189
Cotara - Drug Profile 191
CPC-410 - Drug Profile 193
BC-821 - Drug Profile 194
NOX-A-12 - Drug Profile 195
cintredekin besudotox - Drug Profile 197
Trans Sodium Crocetinate - Drug Profile 199
APG-101 - Drug Profile 200
LB-100 - Drug Profile 202
sitimagene ceradenovec - Drug Profile 203
AT-101 - Drug Profile 205
NXD-30001 - Drug Profile 209
X-396 - Drug Profile 211
X-379 - Drug Profile 212
dasatinib + [bevacizumab] - Drug Profile 213
cetuximab + [irinotecan hydrochloride] + Radiation Therapy - Drug Profile 214
tandutinib - Drug Profile 215
CMV specific cytotoxic T lymphocytes - Drug Profile 216
NHERF-1 - Drug Profile 218
Cytomegalovirus pp65-LAMP mRNA-loaded Dendritic Cell Vaccine - Drug Profile 219
PLX-3397 - Drug Profile 221
PEP-3-KLH conjugate vaccine - Drug Profile 223
Dendritic Cell Vaccine - Drug Profile 224
LXY-1 - Drug Profile 225
DC/AAT + DC/AAT-Flu + DC/KLH - Drug Profile 226
buparlisib - Drug Profile 227
palbociclib - Drug Profile 230
TRC-105 - Drug Profile 232
leflunomide - Drug Profile 234
cilengitide + [temozolomide] + Radiation Therapy - Drug Profile 236
AAV-hIFN-Beta, - Drug Profile 238
ALECSAT - Drug Profile 239
MDX-447 + [Lymphokine-Activated Killer Cells] - Drug Profile 241
Gefitinib + Radiation Therapy - Drug Profile 242
TVI-Brain-1 - Drug Profile 243
rebastinib - Drug Profile 245
afatinib + [temozolomide] - Drug Profile 247
bortezomib + [bevacizumab] - Drug Profile 249
Autologous CD133 Positive BTSC mRNA Pulsed Autologous Dendritic Cell Vaccine - Drug Profile 250
CMV-autologous lymphocyte transfer - Drug Profile 251
lucanthone + temozolomide + radiation therapy - Drug Profile 305
sodium dichloroacetate - Drug Profile 307
TP-0903 - Drug Profile 309
PBT-519 - Drug Profile 310
IB-10A111 - Drug Profile 311
LB-102 - Drug Profile 312
Hydroxychloroquine - Drug Profile 313
carmustine SR - Drug Profile 314
NCE-001 - Drug Profile 315
NOV110201 - Drug Profile 316
Delta24-RGD - Drug Profile 317
procarbazine hydrochloride - Drug Profile 318
SOM-0777 - Drug Profile 319
pritumumab - Drug Profile 320
Eir-060 - Drug Profile 322
Drug For Glioblastoma And Brain Metastatized Systemic Cancers - Drug Profile 323
Anti-miR-10b - Drug Profile 324
picropodophyllin - Drug Profile 325
GNE-317 - Drug Profile 326
STE-301 - Drug Profile 327
STE-401 - Drug Profile 328
DNX-2401 - Drug Profile 329
gabapentin - Drug Profile 331
litenimod - Drug Profile 332
ARN-7016 - Drug Profile 334
Program For Glioblastoma - Drug Profile 335
disulfiram - Drug Profile 336
EphrinA1 Derived Cytotoxins - Drug Profile 337
Recombinant Delivery Proteins Derived From Interleukin-13 - Drug Profile 338
Cancer Vaccine + CpG + Lysate - Drug Profile 339
Fsn-0503h - Drug Profile 340
Compound-22 - Drug Profile 341
EDL-291 - Drug Profile 342
Drug For Glioblastoma Multiforme - Drug Profile 343
Astrocytoma Therapeutics - Drug Profile Updates 344
Astrocytoma Therapeutics - Discontinued Products 392
Astrocytoma Therapeutics - Dormant Products 394
Astrocytoma - Product Development Milestones 401
Featured News and Press Releases 401
Appendix 411
Methodology 411
Coverage 411
Secondary Research 411
Primary Research 411
Expert Panel Validation 411
Contact Us 412
Disclaimer 412



List of Tables

Number of Products Under Development for Astrocytoma, H1 2013 24
Products under Development for Astrocytoma - Comparative Analysis, H1 2013 25
Number of Products under Development by Companies, H1 2013 27
Number of Products under Development by Companies, H1 2013 (Contd..1) 28
Number of Products under Development by Companies, H1 2013 (Contd..2) 29
Number of Products under Development by Companies, H1 2013 (Contd..3) 30
Number of Products under Development by Companies, H1 2013 (Contd..4) 31
Number of Products under Development by Companies, H1 2013 (Contd..5) 32
Number of Products under Investigation by Universities/Institutes, H1 2013 34
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 35
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 36
Comparative Analysis by Late Stage Development, H1 2013 37
Comparative Analysis by Mid Clinical Stage Development, H1 2013 38
Comparative Analysis by Early Clinical Stage Development, H1 2013 39
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 40
Products under Development by Companies, H1 2013 41
Products under Development by Companies, H1 2013 (Contd..1) 42
Products under Development by Companies, H1 2013 (Contd..2) 43
Products under Development by Companies, H1 2013 (Contd..3) 44
Products under Development by Companies, H1 2013 (Contd..4) 45
Products under Development by Companies, H1 2013 (Contd..5) 46
Products under Development by Companies, H1 2013 (Contd..6) 47
Products under Development by Companies, H1 2013 (Contd..7) 48
Products under Investigation by Universities/Institutes, H1 2013 49
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 50
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 51
Bristol-Myers Squibb Company, H1 2013 52
Boehringer Ingelheim GmbH, H1 2013 53
F. Hoffmann-La Roche Ltd., H1 2013 54
Amgen Inc., H1 2013 55
Sanofi-Aventis, H1 2013 56
AstraZeneca PLC, H1 2013 57
Eli Lilly and Company, H1 2013 58
Genentech, Inc., H1 2013 59
Antigenics, Inc., H1 2013 60
MedImmune LLC, H1 2013 61
Merck and Co., Inc., H1 2013 62
Lentigen Corporation, H1 2013 63
Sangamo BioSciences, Inc., H1 2013 64
Plexxikon Inc., H1 2013 65
Celltrion, Inc., H1 2013 66
Ark Therapeutics Group plc, H1 2013 67
Novartis AG, H1 2013 68
Actelion Ltd, H1 2013 69
Eisai Co., Ltd., H1 2013 70
Nippon Shinyaku Co., Ltd., H1 2013 71
Pfizer Inc., H1 2013 72
Teva Pharmaceutical Industries Limited, H1 2013 73
Cell Therapeutics, Inc., H1 2013 74
Exelixis, Inc., H1 2013 75
Aduro BioTech, H1 2013 76
Merck KGaA, H1 2013 77
Celldex Therapeutics, Inc., H1 2013 78
ImmunoCellular Therapeutics, Ltd., H1 2013 79
Lixte Biotechnology Holdings, Inc., H1 2013 80
Northwest Biotherapeutics, Inc., H1 2013 81
Cleveland BioLabs, Inc., H1 2013 82
Oncothyreon Inc, H1 2013 83
Peregrine Pharmaceuticals, Inc., H1 2013 84
Transgene SA, H1 2013 85
Prana Biotechnology Limited, H1 2013 86
Threshold Pharmaceuticals, Inc., H1 2013 87
ThromboGenics NV, H1 2013 88
Proximagen Neuroscience plc., H1 2013 89
Rexahn Pharmaceuticals, Inc., H1 2013 90
Nanobiotix, H1 2013 91
Spectrum Pharmaceuticals, Inc., H1 2013 92
Colby Pharmaceutical Company, H1 2013 93
INSYS Therapeutics, Inc., H1 2013 94
Ambit Biosciences Corporation, H1 2013 95
Fusion Antibodies Ltd, H1 2013 96
immatics biotechnologies GmbH, H1 2013 97
Apogenix GmbH, H1 2013 98
EnGeneIC Ltd, H1 2013 99
Ascenta Therapeutics, Inc., H1 2013 100
Diffusion Pharmaceuticals LLC, H1 2013 101
MacroGenics, Inc., H1 2013 102
Fina Biotech, H1 2013 103
Arno Therapeutics, Inc., H1 2013 104
Deciphera Pharmaceuticals, LLC, H1 2013 105
Vascular Biogenics Ltd., H1 2013 106
Stemline Therapeutics, Inc., H1 2013 107
BioCancell Therapeutics, Inc., H1 2013 108
Advenchen Laboratories, LLC, H1 2013 109
Viral Genetics, Inc., H1 2013 110
NOXXON Pharma AG, H1 2013 111
ChemoCentryx, Inc., H1 2013 112
TVAX Biomedical, LLC, H1 2013 113
Sirnaomics, Inc., H1 2013 114
TRACON Pharmaceuticals, Inc., H1 2013 115
Nexgenix Pharmaceuticals, LLC, H1 2013 116
Regulus Therapeutics Inc., H1 2013 117
Lee's Pharmaceutical Holdings Limited, H1 2013 118
Lipocine Inc., H1 2013 119
DiscoveryBiomed, Inc., H1 2013 120
TAU Therapeutics, LLC, H1 2013 121
EirGen Pharma Ltd., H1 2013 122
CytoVac A/S, H1 2013 123
Ampio Pharmaceuticals, Inc., H1 2013 124
CytomX, LLC., H1 2013 125
Assessment by Monotherapy Products, H1 2013 126
Assessment by Combination Products, H1 2013 127
Assessment by Stage and Route of Administration, H1 2013 130
Assessment by Stage and Molecule Type, H1 2013 133
Astrocytoma Therapeutics - Drug Profile Updates 354
Astrocytoma Therapeutics - Discontinued Products 402
Astrocytoma Therapeutics - Discontinued Products (Contd..1) 403
Astrocytoma Therapeutics - Dormant Products 404
Astrocytoma Therapeutics - Dormant Products (Contd..1) 405
Astrocytoma Therapeutics - Dormant Products (Contd..2) 406
Astrocytoma Therapeutics - Dormant Products (Contd..3) 407
Astrocytoma Therapeutics - Dormant Products (Contd..4) 408
Astrocytoma Therapeutics - Dormant Products (Contd..5) 409
Astrocytoma Therapeutics - Dormant Products (Contd..6) 410



List of Figures

Number of Products under Development for Astrocytoma, H1 2013 24
Products under Development for Astrocytoma - Comparative Analysis, H1 2013 25
Products under Development by Companies, H1 2013 26
Products under Investigation by Universities/Institutes, H1 2013 33
Late Stage Products, H1 2013 37
Mid Clinical Stage Products, H1 2013 38
Early Clinical Stage Products, H1 2013 39
Discovery and Pre-Clinical Stage Products, H1 2013 40
Assessment by Monotherapy Products, H1 2013 126
Assessment by Combination Products, H1 2013 127
Assessment by Route of Administration, H1 2013 128
Assessment by Stage and Route of Administration, H1 2013 129
Assessment by Molecule Type, H1 2013 131
Assessment by Stage and Molecule Type, H1 2013 132

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in the Netherlands

  • December 2016
    18 pages
  • Therapy  

  • Netherlands  

    Canada  

View report >

Therapy Market and Blood Disease Statistics

  • December 2016
    8 pages
  • Therapy  

    Blood Disease  

View report >

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Related Market Segments :

Therapy

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.